Ocrelizemab approved for use by NHS across
A small number of Multiple Scleroris sufferers could soon have a treatment available to slow their symptoms, after the approval of a new development in the UK.
Scientists believe 'Ocrelizumab' could delay the need for a wheelchair by seven years, and it's been approved for routine NHS use across - but not yet on the Isle of Man.
The treatment is recommended by NICE as an option for the treatment of some adult patients with relapsing-remitting MS (RRMS) already.
RRMS is the most common type of MS, accounting for approximately 85% of sufferers.
However, it's thought it also now works for Primary Progressive MS, a particular type of the condition, which accounts for around 10-15% of sufferers - there are roughly 25 PPMS patients on the Island.
Patients also need to meet certain criteria to be eligible.
It has been approved if they:
• Have had symptoms of primary progressive MS for 15 years or less and
• Are able to walk 20 metres or more, with or without walking aids and
• Have evidence of MS activity on MRI scans.
Therefore the number of people who fit these criteria will be small.
Georgina Carr, from the UK MS Society, says it's a huge step:
MHK calls for probe into Island's financial services and eGaming frameworks
Manx mum 'confident' neurodiversity training for all teachers will come to fruition
Windfarm consultation closing
Onchan Commissioners 'pleased' police drop in sessions resuming in village
Agricultural vet services and GP ratios on Tynwald question paper